Loknete Dr. J. D. Pawar College of Pharmacy, Manur, Kalwan, Nashik- 423501, Maharashtra, Nashik, India
One common cardiovascular condition that needs to be effectively managed is hypertension. A beta-blocker called atenolol is frequently used to treat hypertension. Using tamarind seed kernel powder (TSKP) as a natural disintegrant, the study sought to create and assess atenolol tablets. TSKP was used in the formulation of the tablets, and their physical properties, dissolves profile, and disintegration time were assessed. The tablets quick and total dissolving, as demonstrated by the results, suggested that TSKP might be used as a natural disintegrant. By demonstrating the feasibility of using Tamarind seed kernel powder is a naturally occurring disintegrant in atenolol tablets, this work offers a feasible approach for the creation of naturally derived excipient-based hypertension therapy drugs.
Millions of people throughout the world suffer from hypertension, a common cardiovascular condition that requires efficient treatment methods. A typical beta-blocker used to treat hypertension is atenolol, which lowers heart rate and blood pressure1. For atenolol, tablet formulation is a commonly utilized dosage form because of its patient compliance and ease of administration. However, synthetic disintegrants, which are typically used in regular tablets, have drawbacks, including the propensity to irritate the gastrointestinal tract and be costly. Natural excipients have drawn a lot of interest lately because of their affordability, biocompatibility, and biodegradability2. A natural polymer made from Tamarindus indica seeds is called tamarind seed kernel powder (TSKP). Because TSKP exhibits outstanding disintegrant, swelling, and mucoadhesive qualities, it has been investigated as a possible excipient in medicinal formulations. The purpose of this study is to create and test atenolol tablets with TSKP as a natural disintegrant, examining its potential to improve tablet disintegration rate while providing a more patient-friendly and cost-effective alternative to synthetic disintegrants.
Figure 1. Structure of Tamarind Seed Polysaccharide.
Figure 2. Tamarind Seed. Figure 3. Tamarind Kernel Powder.
2.Disintegration Property of Tamarind Kernel Powder1,2:
TKP's disintegration mechanism consists of several essential factors:
Figure 4. Disintegration Property of Tamarind Kernel Powder.
3. Identification Test for Tamarind Kernel Powder3:
4. MATERIALS AND METHODS:
MATERIALS:
Figure 5. Materials.
Used For Preparation of Fast Disintegrating Tablet:
Figure 6. Method Used for Preparation of Fast Disintegrating Tablet (Direct Compression).
Methods Used to Prepare Rapid Disintegrating Tablets3:
Table 1. Methods Used to Prepare Rapid Disintegrating Tablet.
5. Formulation Table:
Table 2. Formulation Table
Sr. No |
Ingredients |
F1 |
F2 |
F3 |
F4 |
F5 |
F6 |
1 |
Atenolol |
100 |
100 |
100 |
100 |
100 |
100 |
2 |
TKP |
5 |
7.5 |
10 |
15 |
20 |
30 |
3 |
MCC |
200 |
200 |
195 |
190 |
190 |
180 |
4 |
Lactose |
77 |
72.5 |
75 |
75 |
70 |
70 |
5 |
Mg. Stearate |
8 |
10 |
10 |
10 |
10 |
10 |
6 |
Talc |
5 |
5 |
5 |
5 |
5 |
5 |
7 |
Avg. Wt. |
395 |
395 |
395 |
395 |
395 |
395 |
6. Pharmacological Properties of Atenolol Drug4:
1)Well, absorbed when taken orally (50–60%)
2)Distribution: widely dispersed, with the kidneys, liver, and heart having the highest quantities. 3)There is very little hepatic metabolism.
4)Elimination: Mostly eliminated unaltered in urine (85–100%)
7. Pre-Compression Studies of Tamarind Kernel Powder:
Table 3. Pre-Compression Studies of Tamarind Kernel Powder.
1)Bulk Density: |
Pouring the powder blend into a cylinder and recording its initial weight allows for calculation. Bulk volume is the starting volume. The following formula was used to determine the volume of the powder blend. Formula: Bulk Density: Mass of powder Volume of powder |
2)Tapped Density: |
It can be defined as the ratio of a powder's tapped volume to its overall mass. The powder blend was poured into the measuring cylinder to ascertain it. On the harder surface, the cylinder was gently tapped 500 times, and the volume of powder that was tapped was recorded. The tapped volume was recorded after 1000 repetitions of tapping when there was a difference of more than 2% between two volumes. In a bulk density apparatus, tapping was carried out repeatedly until the ensuing volume differences were less than 2%. It was computed using the formula and expressed in g/ml5. Formula: Tapped density: Mass of powder Tapped volume of powder |
3)Angle of Repose: |
To get the angle of repose, we applied the funnel approach. The mixture was run through a funnel that could be adjusted vertically until the cone's height (h) was attained. The Angle of Repose (θ) was calculated using the formula after the heap's radius (r) was measured6. Formula: Angle of Repose: Tan θ: h r |
4)Hausner’s Ratio: |
HR serves as a proxy for powder flow ease. It is computed using the formula that follows7: Formula: Hausner’s Ratio: Tapped density Bulk density |
5)Carr’s Index: |
It proves that the flow of a powder is what makes it compressible. The following is the Carr's index formula11: Formula: Carr’s index: Dt-Db × 100 Dt |
8.Post-Compression Studies of Tamarind Kernel Powder:
Table 4. Post-Compression Studies of Tamarind Kernel Powder.
1)Tablet Hardness: |
In a test device that applies tension or bending stress, the force needed to shatter a tablet is called "tablet hardness." The effectiveness and overall performance of a tablet are greatly influenced by its hardness, especially in relation for patients use, packaging, and shipping12. |
||||||||||||||||||||
2)Tablet Thickness: |
Tablets were measured for thickness with a Vernier caliper. |
||||||||||||||||||||
3)Weight Variation: |
A test for weight variation was conducted to make sure a tablet had the right amount of medication. Analytical balances were used to determine the weight of each tablet. That was used to calculate the average weight. Next, each tablet's weight was compared to the average weight8. Weight of 10 tablets (mg) Table 5. Weight of Tablets
10 tablets average weight is 386.5 mg. Weight variation restriction for tablets weighing <500 mg in accordance with different regulatory recommendations and pharmacopoeias: USP (United States Pharmacopoeia): For tablets < 250 mg: ±10% For tablets 250-500 mg: ±5% Calculation : Average weight of 1 tablet = 395 mg 395 x 5 / 100 = 19.75 mg 395 ± 19.75 = 414.75 or 375.25 |
||||||||||||||||||||
4)Friability: |
A sample of ten to twenty tablets was tested for friability using a USP-type Roche friabilator. Apparatus: A cylindrical drum (285 mm diameter, 190 mm depth) with a translucent plastic cover and a removable tray. Formula: Initial weight – Final weight ×100 Initial weight Calculation: 3865 – 3835×100 =0.7 3865 |
||||||||||||||||||||
5)In Vitro Disintegration: |
The tablet disintegrating test device was used to determine the tablet's disintegration time. Each tube of the tablet disintegration testing device contained six tablets. The media was kept at 37 ± 2°C, and the amount of time needed for the complete pill to dissolve was recorded. The duration required for a tablet or capsule to disintegrate in a controlled laboratory setting that mimics physiological fluids is known as the "in vitro disintegration time." Test Method: Apparatus: A USP Disintegration Apparatus or the disintegration tester with baskets13. Medium: Distilled Water Procedure: Put four tablets in baskets, then immerse them in a medium that is maintained at 37°C and watch. |
||||||||||||||||||||
6)In Vitro Dissolution: |
A technique used in laboratories to mimic how a pharmaceutical product might dissolve in the human body is called in vitro dissolution testing. The test assesses the active pharmaceutical ingredient's (API) rate and degree of dissolution from the dosage form9. The contents of the dissolution medium are as follows: [900 milliliter Phosphate Buffer: Ph 6.8] Test:
(5, 10, 15, 30, 45, 60 min.)
Amount of drug release(mg/ml): Concentration × Dissolution volume × Dilution factor 1000 Percent Drug release: Amount of drug release ×1000 Total amount of drug in formulation (mg) |
||||||||||||||||||||
7)UV Absorbance: |
The concept an active pharmaceutical ingredient (API)-containing solution's ability to absorb ultraviolet (UV) light is measured by the UV Absorbance test. The API's concentration and absorbance are intimately correlated. Measurement Steps for UV Absorbance:
|
9.UV Absorbance And % Drug Release for Trial Batches. ( F1,F2,F3,F4):
Table 6. UV Absorbance and % Drug Release for Trial Batches. ( F1,F2,F3,F4)
Sr no. |
Time (min) |
Absorbance |
Concentration (ug/ml) |
% Drug Release |
||||||||||
F1 |
F2 |
F3 |
F4 |
F1 |
F2 |
F3 |
F4 |
F1 |
F2 |
F3 |
F4 |
|
||
1. |
5 |
0.014 |
0.015 |
0.020 |
0.029 |
0.24 |
0.29 |
0.54 |
0.99 |
2.20 |
2.85 |
4.48 |
6.95 |
|
2. |
10 |
0.029 |
0.32 |
0.038 |
0.046 |
0.99 |
1.14 |
1.44 |
1.845 |
4.95 |
8.30 |
9.05 |
11.60 |
|
3. |
15 |
0.052 |
0.57 |
0.065 |
0.076 |
2.14 |
2.39 |
2.79 |
3.34 |
9.30 |
14.55 |
18.11 |
24.06 |
|
4. |
30 |
0.081 |
0.86 |
0.097 |
0.13 |
3.59 |
3.84 |
4.09 |
6.04 |
13.35 |
22.75 |
29.85 |
39.40 |
|
5. |
45 |
0.10 |
0.10 |
0.12 |
0.15 |
4.54 |
4.54 |
5.54 |
7.04 |
19.90 |
30.90 |
45.90 |
56.40 |
|
6. |
60 |
0.11 |
0.13 |
0.15 |
0.20 |
5.045 |
6.04 |
7.04 |
9.54 |
28.40 |
39.40 |
53.40 |
68.90 |
|
10.Observation Table: F5 UV Absorbance and Percent Drug Release:
Table 7.F5 Batch UV Absorbance and Percent Drug Release.
Sr. No |
Time (min) |
Absorbance |
Concentration(μg/ml) |
% Drug Release |
1 |
5 |
0.035 |
1.295 |
7.15 |
2 |
10 |
0.057 |
2.39 |
21.55 |
3 |
15 |
0.083 |
3.69 |
33.25 |
4 |
30 |
0.15 |
7.045 |
63.40 |
5 |
45 |
0.190 |
9.04 |
71.40 |
6 |
60 |
0.23 |
11.04 |
82.40 |
Observation Table F6 Batch (UV Absorbance):
Table 8.F6 Batch UV Absorbance and Percent Drug Release.
Sr. No |
Time (min) |
Absorbance |
Concentration(μg/ml) |
Wavelength (nm) |
1 |
5 |
0.05 |
2.045 |
226 |
2 |
10 |
0.08 |
3.545 |
226 |
3 |
15 |
0.11 |
5.045 |
226 |
4 |
30 |
0.18 |
8.54 |
226 |
5 |
45 |
0.22 |
10.54 |
226 |
6 |
60 |
0.27 |
13.045 |
226 |
Figure 8. Calibration Curve of Atenolol (F6)
Figure 9. Time vs Drug Release.
11.Comparative Study of Time Vs Percent Drug Release of All Batches (F1, F2, F3, F4, F5, F6):
Figure 10. Comparative Study of Time vs % Drug Release of All Batches.(F1,F2,F3,F4,F5,F6)
12.RESULT AND DISCUSSION:
1)Pre-Compression Evaluation:
Table 9. Pre-compression Parameters
Sr. No |
Test |
Standard Value |
Observed Value |
Conclusion |
|
Bulk Density |
0.40 – 0.60 g/ml |
0.38 g/ml |
Very loose |
|
Tapped Density |
0.58 – 0.78 g/ml |
0.60 g/ml |
Very loose |
|
Angle of Repose |
300 – 450 |
380 |
Moderate Flow |
|
Carr’s Index |
21 – 27 % |
20 % |
Fair |
|
Hausner Ratio |
1.2 – 1.5 |
1.29 |
Passable |
2)Post-Compression Evaluation:
Table 10. Post-compression Parameters
Sr. No |
Parameter |
Standard Value |
Observed Value |
Conclusion |
|
Hardness |
4 – 12 kg/cm 2 |
4.1 kg/cm 2 |
Low |
|
Thickness |
5 – 10 mm |
10 mm |
Pass |
|
Friability |
0.5 – 1 % |
0.7 % |
Excellent |
|
Weight Variation |
>500 mg ± 5% |
414.75 or 375.25 |
Acceptable |
|
Disintegration |
<15 min |
9 min 52 sec |
Good |
|
% Drug Release T90 |
30 – 60 min |
42.67 min |
Good |
13.CONCLUSION:
According to the natural tamarind kernel powder's pre-compression and post-compression evaluation parameters listed above, our optimized F6 batch passes each of them, and the results were determined to be satisfactory within the given bounds, demonstrating good disintegrating property.
REFERENCES
Aakanksha Pagar,* Jayshree Bhadane, Development and Assessment of Naturally Derived Tamarind Kernel powder as Disintegrant in Beta-Blocker Atenolol Tablet, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 3, 2133-2143 https://doi.org/10.5281/zenodo.15077194